ReviewBiochimica et biophysica acta2011
Current status of molecular markers for early detection of sporadic pancreatic cancer.
Review in Biochimica et biophysica acta, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 4 syntheses or guidelines pooled it, 92 citations in OpenAlex.
- Prognostic significance of cyclooxygenase-2 protein in pancreatic cancer: a meta-analysis.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Pooled it
- Serum carbohydrate antigen 242 expression exerts crucial function in the diagnosis of pancreatic cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Pooled it
- CA19-9 and CA242 as tumor markers for the diagnosis of pancreatic cancer: a meta-analysis.Clinical and experimental medicine · 2014Pooled it
- A meta analysis of pancreatic microarray datasets yields new targets as cancer genes and biomarkers.PloS one · 2014Pooled it
- Pancreatic endocrine and exocrine signaling and crosstalk in physiological and pathological status.Signal transduction and targeted therapy · 2025Review
- Selective epigenetic alterations in RNF43 in pancreatic exocrine cells from high-fat-diet-induced obese mice; implications for pancreatic cancer.BMC research notes · 2024Article
- Advances in Pancreatic Cancer Treatment by Nano-Based Drug Delivery Systems.Pharmaceutics · 2023Review
- Identification of technology frontiers of artificial intelligence-assisted pathology based on patent citation network.PloS one · 2022Review
- Gastrointestinal Cancer Stage at Diagnosis Before and During the COVID-19 Pandemic in Japan.JAMA network open · 2021Article
- The Case for GNMT as a Biomarker and a Therapeutic Target in Pancreatic Cancer.Pharmaceuticals (Basel, Switzerland) · 2021Article
- CpG Island Methylator Phenotype Modulates the Immune Response of the Tumor Microenvironment and Influences the Prognosis of Pancreatic Cancer Patients.Journal of oncology · 2021Article
- Acinar transformed ductal cells exhibit differential mucin expression in a tamoxifen-induced pancreatic ductal adenocarcinoma mouse model.Biology open · 2020Article
- Mucins in pancreatic cancer: A well-established but promising family for diagnosis, prognosis and therapy.Journal of cellular and molecular medicine · 2020Review
- Calcium Signaling Alterations Caused by Epigenetic Mechanisms in Pancreatic Cancer: From Early Markers to Prognostic Impact.Cancers · 2020Article
- Article
- Role of the microbiome in occurrence, development and treatment of pancreatic cancer.Molecular cancer · 2019Review
- A Label-Free Electrochemical Immunosensor for Detection of the Tumor Marker CA242 Based on Reduced Graphene Oxide-Gold-Palladium Nanocomposite.Nanomaterials (Basel, Switzerland) · 2019Article
- Graviola attenuates DMBA-induced breast cancer possibly through augmenting apoptosis and antioxidant pathway and downregulating estrogen receptors.Environmental science and pollution research international · 2019Article
- Preclinical pharmacodynamic evaluation of a new Src/FOSL1 inhibitor, LY-1816, in pancreatic ductal adenocarcinoma.Cancer science · 2019Article
- Pancreatic cancer associated with obesity and diabetes: an alternative approach for its targeting.Journal of experimental & clinical cancer research : CR · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Pancreatic cancer (PC) is a highly lethal malignancy with near 100% mortality. This is in part due to the fact that most patients present with metastatic or locally advanced disease at the time of diagnosis. Significantly, in nearly 95% of PC patients there is neither an associated family history of PC nor of diseases known to be associated with an increased risk of PC. These groups of patients who comprise the bulk of PC cases are termed as "sporadic PC" in contrast to the familial PC cases that comprise only about 5% of all PCs. Given the insidious onset of the malignancy and its extreme resistance to chemo and radiotherapy, an abundance of research in recent years has focused on identifying biomarkers for the early detection of PC, specifically aiming at the sporadic PC cohort. However, while several studies have established that asymptomatic individuals with a positive family history of PC and those with certain heritable syndromes are candidates for PC screening, the role of screening in identifying sporadic PC is still an unsettled question. The present review attempts to assess this critical question by investigating the recent advances made in molecular markers with potential use in the early diagnosis of sporadic PC - the largest cohort of PC cases worldwide. It also outlines a novel yet simple risk factor based stratification system that could be potentially employed by clinicians to identify those individuals who are at an elevated risk for the development of sporadic PC and therefore candidates for screening.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.